前列腺癌体细胞肿瘤检测:三级医疗中心经验及病理医生驱动的局限性肿瘤诊断时反射检测
本研究评估了516例前列腺癌样本的体细胞DNA损伤修复基因突变频率、分布及病理相关性。结果显示35.5%患者至少有一个变异,13.9%有至少一个I/II级变异,21.5%有III级变异。I/II级变异与分级分组或导管内/筛状癌存在无显著关联,病理参数可能无法可靠指导患者选择。
要点
- 体细胞检测可发现临床可操作的DNA损伤修复基因变异。
- 病理医生驱动的反射检测可 streamline 结果用于临床决策。
- 分级分组和导管内/筛状癌不能可靠预测I/II级变异存在。
核心结论
- 体细胞肿瘤检测可发现前列腺癌中具有临床意义的变异,病理医生发起的反射检测有助于临床决策。
研究设计与样本
- 回顾性队列研究,纳入516例前列腺癌样本,使用定制二代测序面板检测同源重组修复和错配修复基因。
主要发现
- 183例(35.5%)患者至少有一个变异,其中72例(13.9%)有至少一个I级或II级变异,111例(21.5%)有III级变异。
- 转移活检样本中I/II级变异检出率为27%(12/44),原发样本为13%(61/472)。
- 12%(62/516)患者在同源重组修复基因有至少一个I/II级变异,2.9%(10/516)在错配修复基因有至少一个I/II级变异。
- I/II级变异的存在与分级分组或原发肿瘤中导管内/筛状癌存在无显著关联。
- 在309例反射检测的激素初治原发肿瘤中,I/II级变异检出率为10%(31/309),其中GG2为9.2%(9/98),GG3为9%(9/100),GG4为9.1%(4/44),GG5为13.4%(9/67)。
关键数值与推荐
- 变异分类基于分子病理学协会/美国临床肿瘤学会/美国病理学家学会指南。
临床怎么用
- 体细胞肿瘤检测可用于检测前列腺癌中具有临床意义的变异,病理医生驱动的反射检测可简化结果获取以支持临床决策。
- 分级分组和导管内/筛状癌存在可能不是可靠的患者选择指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Somatic tumor testing in prostate cancer (PCa) can guide treatment options by identifying clinically actionable variants in DNA damage repair genes, including acquired variants not detected using germline testing alone. Guidelines currently recommend performing somatic tumor testing in metastatic PCa, whereas there is no consensus on the role of testing in regional disease, and the optimal testing strategy is only evolving. This study evaluates the frequency, distribution, and pathologic correlates of somatic DNA damage repair mutations in metastatic and localized PCa following the implementation of pathologist-driven reflex testing at diagnosis. A cohort of 516 PCa samples were sequenced using a custom next-generation sequencing panel including homologous recombination repair and mismatch repair genes. Variants were classified based on the Association for Molecular Pathology/American Society of Clinical Oncology/College of American Pathologists guidelines. In total, 183 (35.5%) patients had at least one variant, which is as follows: 72 of 516 (13.9%) patients had at least 1 tier I or tier II variant, whereas 111 of 516 (21.5%) patients had a tier III variant. Tier I/II variant(s) were identified in 27% (12/44) of metastatic biopsy samples and 13% (61/472) of primary samples. Overall, 12% (62/516) of patients had at least 1 tier I/II variant in a homologous recombination repair gene, whereas 2.9% (10/516) had at least 1 tier I/II variant in a mismatch repair gene. The presence of a tier I/II variant was not significantly associated with the grade group (GG) or presence of intraductal/cribriform carcinoma in the primary tumor. Among the 309 reflex-tested hormone-naive primary tumors, tier I/II variants were identified in 10% (31/309) of cases, which is as follows: 9.2% (9/98) GG2; 9% (9/100) GG3; 9.1% (4/44) GG4; and 13.4% (9/67) GG5 cases. Our findings confirm the use of somatic tumor testing in detecting variants of clinical significance in PCa and provide insights that can inform the design of testing strategies. Pathologist-initiated reflex testing streamlines the availability of the results for clinical decision-making; however, pathologic parameters such as GG and the presence of intraductal/cribriform carcinoma may not be reliable to guide patient selection.
引用
- Prendeville S, Kaur H, Ansari S, et al. Somatic Tumor Testing in Prostate Cancer: Experience of a Tertiary Care Center Including Pathologist-Driven Reflex Testing of Localized Tumors at Diagnosis. Mod Pathol. 2024. PMID: 38588883. doi:10.1016/j.modpat.2024.100489
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。